VTVTHealthcare · BiotechnologyThe 6 Wall Street analysts covering vTv Therapeutics, Inc. hold a median 12-month price target of $56 — +72.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 87 of 100 as at 1 Aug 2026 — inside the top quartile. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores vTv Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Growth (93): Sales and profits are climbing, and climbing faster than before.
Accruals (11): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.
The rank is the raw material. Whether the rules would actually own vTv Therapeutics, Inc. — and when they’d sell — is the membership.
The bullish and bearish analyst opinions on VTVT, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +72.9% from it.
Of the 20 most recent actions, 3 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 16 July 2026 | BTIG | Maintains | Buy | $49 → $57 |
| 12 Mar 2026 | Evercore ISI Group | Initiates | Outperform | — |
| 11 Mar 2026 | BTIG | Reiterates | Buy | — |
| 27 Jan 2026 | BTIG | Maintains | Buy | — |
| 23 Jan 2026 | Roth Capital | Initiates | Buy | — |
| 5 Jan 2026 | TD Cowen | Initiates | Buy | — |
| 19 Dec 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 19 Nov 2025 | BTIG | Initiates | Buy | — |
| 13 Aug 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 9 Apr 2025 | HC Wainwright & Co. | Initiates | Buy | — |
| 9 Dec 2024 | Alliance Global Partners | Initiates | Buy | — |
| 7 Mar 2023 | HC Wainwright & Co. | Reiterates | Buy | $6.00 |
| 17 Aug 2022 | Northland Capital Markets | Maintains | Outperform | $1.50 → $2.00 |
| 18 Feb 2022 | Cantor Fitzgerald | Initiates | Overweight | — |
| 10 Feb 2020 | H.C. Wainwright | Reiterates | Buy | — |
| 10 Feb 2020 | HC Wainwright & Co. | Reiterates | Buy | $5.00 → $6.00 |
| 30 May 2019 | H.C. Wainwright | Initiates | Buy | — |
| 30 May 2019 | HC Wainwright & Co. | Initiates | Buy | — |
| 6 May 2019 | Northland Capital Markets | Upgrade | Outperform | — |
| 10 Apr 2018 | Northland Capital Markets | Downgrade | Market Perform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 93% of US stocks
Cheaper than 37% of US stocks
Cheaper than 24% of US stocks
Cheaper than 96% of US stocks
Higher than 99% of US stocks
Higher than 62% of US stocks
Higher than 42% of US stocks
Higher than 35% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. VTVT appears on the weeks it earns a place.
vTv Therapeutics granted 23,500 stock options to two non-executive employees as a material inducement to employment, in accordance with Nasdaq Listing Rule 5635(c)(4).
Why it matters — This standard corporate action reflects the company's effort to attract talent as it advances cadisegliatin, a potential first-in-class therapy for type 1 diabetes.
The 6 Wall Street analysts covering vTv Therapeutics, Inc. have a median 12-month price target of $56, with estimates ranging from $44 to $67. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 6 analysts covering vTv Therapeutics, Inc., 6 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks vTv Therapeutics, Inc. 87 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 1 Aug 2026, vTv Therapeutics, Inc. ranks 87 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (93 of 100).
No one can know that. What the data says: the median 12-month target from 6 analysts implies +72.9% from the last close, and Ticker Nerd's factor model ranks vTv Therapeutics, Inc. 87 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering vTv Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for VTVT are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $44 to $67 over the next 12 months.
vTv Therapeutics, Inc. returned +122.2% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing oral small molecule drug candidates to treat diabetes and other chronic diseases.
The most recent item we track (GlobeNewsWire, 28 July 2026): "vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)". vTv Therapeutics granted 23,500 stock options to two non-executive employees as a material inducement to employment, in accordance with Nasdaq Listing Rule 5635(c)(4).
vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing oral small molecule drug candidates to treat diabetes and other chronic diseases. Its lead product candidate, cadisegliatin (TTP399), is an orally administered, liver-selective glucokinase activator in Phase 3 clinical trials as a potential adjunctive therapy to insulin for type 1 diabetes patients. The company advances additional molecules targeting metabolic and inflammatory conditions, including TTP273, an oral glucagon-like peptide 1 receptor agonist for type 2 diabetes; HPP737, a non-central nervous system penetrant phosphodiesterase type 4 inhibitor for inflammatory diseases; and others such as HPP593, Azeliragon, and HPP3033 addressing oxidative stress-related disorders. vTv Therapeutics Inc. maintains license agreements, including with Newsoara Biopharma for phosphodiesterase type 4 inhibitors like HPP737, supporting global development efforts. Founded in 2015 and headquartered in High Point, North Carolina, the company operates in the biotechnology sector, emphasizing innovative oral treatments to address unmet needs in chronic disease management.
CEO Mr. Paul J. Sekhri · 26 employees · United States · https://vtvtherapeutics.com